AVXLHealthcare · BiotechnologyThe 1 Wall Street analysts covering Anavex Life Sciences Corp. hold a median 12-month price target of $20 — +1242.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Anavex Life Sciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (82): Sales and profits are climbing, and climbing faster than before.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVXL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1242.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Mar 2026 | D. Boral Capital | Maintains | Buy | $24 |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | $24 |
| 23 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 6 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 Oct 2025 | Jones Trading | Downgrade | Hold | — |
| 7 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVXL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Anavex Life Sciences Corp. returned −84.3% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 60% of US stocks
Cheaper than 66% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 34% of US stocks
Higher than 27% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Anavex Life Sciences Corp. has a market value of $142.8M and an enterprise value of $23.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$13.0M.
Diluted earnings per share, trailing twelve months: $−0.15.
Free cash flow in the twelve months to 30 June 2026: −$29.3M.
Trailing P/E: −2.7×; forward P/E: −2.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Anavex Life Sciences Corp. employs 34 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Anavex Life Sciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Law Offices of Frank R. Cruz announced that investors who incurred losses related to Anavex Life Sciences Corp. have an opportunity to lead a securities fraud class action lawsuit.
Why it matters — The announcement concerns a securities fraud lawsuit involving Anavex and may be relevant to shareholders following legal matters related to the company.
Glancy Prongay Wolke & Rotter LLP reminded Anavex investors of a November 30, 2026 deadline to seek lead-plaintiff status in a securities class action. The case covers investors who acquired Anavex securities from November 26, 2025, through August 28, 2026.
Why it matters — The notice concerns a securities lawsuit and a filing deadline relevant to AVXL shareholders who acquired shares during the stated period.
SueWallSt reminded Anavex Life Sciences shareholders of a November 30, 2026 lead plaintiff deadline in a lawsuit. The excerpt says Anavex has stated that Board reviews and executive certifications could have relied on incomplete information and advises investors to rely only on revised clinical trial descriptions.
Why it matters — The lawsuit deadline and statements about potentially incomplete information and revised trial descriptions are relevant to AVXL shareholders monitoring the company’s disclosures.
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Anavex on behalf of investors who acquired its securities from November 26, 2025, through August 28, 2026. The firm is encouraging investors who suffered losses to contact it before November 30, 2026.
Why it matters — The lawsuit announcement concerns Anavex investors and the specified class period, making it relevant to AVXL shareholders monitoring legal developments.
Kirby McInerney LLP announced that investors who purchased Anavex Life Sciences securities may contact the firm about a securities fraud class action. The notice asks interested investors to make contact by November 30, 2026, to discuss their rights or interests at no cost.
Why it matters — The notice concerns a securities fraud lawsuit involving Anavex and provides a deadline for investors to contact the law firm.
The 1 Wall Street analysts covering Anavex Life Sciences Corp. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Anavex Life Sciences Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anavex Life Sciences Corp. 24 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Anavex Life Sciences Corp. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1242.3% from the last close, and Ticker Nerd's factor model ranks Anavex Life Sciences Corp. 24 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Anavex Life Sciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
Anavex Life Sciences Corp. returned -84.3% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders.
The most recent item we track (PRNewsWire, 8 Oct 2026): "Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit". The Law Offices of Frank R. Cruz announced that investors who incurred losses related to Anavex Life Sciences Corp. have an opportunity to lead a securities fraud class action lawsuit.
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases. The company’s work centers on precision medicine approaches designed to address high unmet medical needs in brain health, with a primary emphasis on advancing candidate medicines through clinical development. Anavex Life Sciences Corp. operates in the biotechnology sector and serves as a research-driven participant in the global pharmaceutical market, where it contributes to the development of potential treatments for complex neurological diseases.
CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D. · 34 employees · United States · https://www.anavex.com
